Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
2019 · JAMA Oncology · 277 citations
https://doi.org/10.1001/jamaoncol.2019.0684
E
Erkut Borazanci
HonorHealth(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
319
Papers
4.4K
Citations
27
h-index
48
i10-index
Erkut Borazanci is an academic researcher from HonorHealth. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Cancer Genomics and Diagnostics & Epigenetics and DNA Methylation. The author has an h-index of 27, co-authored 272 publications.
ORCID: 0000-0001-5136-5462Papers by this author
worksResults from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
2019 · Clinical Cancer Research · 250 citations
https://doi.org/10.1158/1078-0432.ccr-18-2992
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
2019 · Oncology · 81 citations
https://doi.org/10.1159/000500571
A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer
2023 · Nature Communications · 32 citations
https://doi.org/10.1038/s41467-023-40798-6
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction
2025 · The Oncologist · 8 citations
https://doi.org/10.1093/oncolo/oyae323
Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma
2025 · British Journal of Cancer · 1 citations
https://doi.org/10.1038/s41416-025-03167-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat